Zymeworks (ZYME) Price & Analysis

Compare

531 Followers

ZYME Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.03 - $17.70

Previous CloseN/A

Volume35.38K

Average Volume (3M)437.64K

Market Cap

$1.07B

Enterprise Value$708.40M

Total Cash (Recent Filing)$281.38M

Total Debt (Recent Filing)$18.68M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Nov 11, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.03

Shares Outstanding75,166,200

10 Day Avg. Volume464,098

30 Day Avg. Volume437,640

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue5.77

Enterprise Value/Gross Profit6.08

Enterprise Value/Ebitda-11.65

Forecast

1Y Price Target

$21.25

Price Target Upside40.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEncouraging data from the ZW191 Phase 1 trial gives the company confidence in advancing ZW251.

Financial PerformanceZymeworks reported significant revenue growth in Q2, surpassing both internal and consensus expectations.

Partnerships And MilestonesZYME's unique ability to leverage milestone payments, royalties, and other partnerships serves as a source of non-dilutive funding that can be reinvested into the pipeline.

Bears Say

Financial StabilityThe company faces a cash burn of $200 million annually with approximately 2 years of cash left, which could impact financial stability.

Investor SentimentInvestors have questioned data timeline pushes from 2H 2024 to 2Q 2025 and 2H 2025.

Trial Data ConcernsThere is some concern about the delay in data release for the HERIZON-GEA-01 trial, although it aligns with original guidance.

Zymeworks News

Zymeworks price target raised to $22 from $19 at Citi

Citi raised the firm’s price target on Zymeworks (ZYME) to $22 from $19 and keeps a Buy rating...

13d ago

ZYME

Zymeworks reports Q2 EPS 3c, consensus (46c)

Reports Q2 revenue $48.73M, consensus $17.18M. The revenue increase was primarily due to a $20M non-refundable milestone from...

16d ago

ZYME

Zymeworks announces FDA clearance of IND application for ZW251

Zymeworks (ZYME) announced the U.S. FDA has cleared the investigational new drug application for ZW251, a novel glypican-3-targeted...

27d ago

ZYME

Zymeworks to Engage in Key Investor Conferences

Zymeworks ( ($ZYME) ) has issued an update. Zymeworks Inc. announced its participation in several upcoming investor conferences,...

5d ago

ZYME

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

Zymeworks (($ZYME)) has held its Q2 earnings call. Read on for the main highlights of the call. The...

11d ago

ZYME

Zymeworks Strengthens Leadership with New Board Appointments

An announcement from Zymeworks ( ($ZYME) ) is now available. Zymeworks Inc. has announced the appointment of Greg...

13d ago

ZYME

Zymeworks Reports Strong Q2 2025 Financial Performance

Zymeworks ( ($ZYME) ) has released its Q2 earnings. Here is a breakdown of the information Zymeworks presented...

16d ago

ZYME

Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating

TD Cowen analyst Yaron Werber has maintained their bullish stance on ZYME stock, giving a Buy rating yesterday....

16d ago

ZYME

Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating

Zymeworks, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from LifeSci...

16d ago

ZYME

Zymeworks Reports Q2 Results and FDA Clearance

Zymeworks ( ($ZYME) ) has shared an update. On August 7, 2025, Zymeworks Inc. reported its second quarter...

16d ago

ZYME

Zymeworks: Promising Pipeline and Strategic Advancements Drive Buy Rating

LifeSci Capital analyst Charles Zhu reiterated a Buy rating on Zymeworks today and set a price target of...

27d ago

ZYME

Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer

An announcement from Zymeworks ( ($ZYME) ) is now available. Zymeworks has announced the FDA clearance of its...

27d ago

ZYME

Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences

An announcement from Zymeworks ( ($ZYME) ) is now available. Zymeworks Inc. announced it will report its second...

1M ago

ZYME

Zymeworks announces NMPA approval of zanidatamab in China

Zymeworks (ZYME) announced that the National Medical Products Administration in China has approved zanidatamab for the treatment of...

3M ago

ZYME

ZYME FAQ

What was Zymeworks Inc’s price range in the past 12 months?

Zymeworks Inc lowest stock price was $9.03 and its highest was $17.70 in the past 12 months.

What is Zymeworks Inc’s market cap?

Zymeworks Inc’s market cap is $1.07B.

When is Zymeworks Inc’s upcoming earnings report date?

Zymeworks Inc’s upcoming earnings report date is Nov 11, 2025 which is in 79 days.

How were Zymeworks Inc’s earnings last quarter?

Zymeworks Inc released its earnings results on Aug 07, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.483 by $0.513.

Is Zymeworks Inc overvalued?

According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zymeworks Inc pay dividends?

Zymeworks Inc does not currently pay dividends.

What is Zymeworks Inc’s EPS estimate?

Zymeworks Inc’s EPS estimate is -0.29.

How many shares outstanding does Zymeworks Inc have?

Zymeworks Inc has 75,166,200 shares outstanding.

What happened to Zymeworks Inc’s price movement after its last earnings report?

Zymeworks Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.483. Following the earnings report the stock price went down -1.151%.

Which hedge fund is a major shareholder of Zymeworks Inc?

Currently, no hedge funds are holding shares in ZYME

Zymeworks Stock Smart Score

Neutral

Fundamentals

Return on Equity

-19.89%

Trailing 12-Months

Asset Growth

-20.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zymeworks Inc

Zymeworks Inc. (NASDAQ: ZYME) is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer and other diseases. The company specializes in its proprietary therapeutic platforms, including Zymeworks' Azymetric and Zymeworks' ZymeLink, which enable the design and production of bispecific antibodies and other multi-specific therapeutics. Zymeworks is engaged in various stages of drug development and collaborates with pharmaceutical partners to advance its pipeline of candidates.

Zymeworks (ZYME) Earnings & Revenues

Historic Earnings Reports

ZYME Company Deck

ZYME Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth, successful regulatory approvals, and promising advancements in the clinical and preclinical pipeline, supported by robust partnerships. However, there were concerns about reduced revenue in specific areas and ongoing cash burn. Additionally, questions about potential delays in the HERIZON-GEA-01 study results were raised.View all ZYME earnings summaries

ZYME Stock 12 Month Forecast

Average Price Target

$21.25

▲(40.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","13":"$13","19":"$19","25":"$25","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13,19,25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.910769230769231,15.251538461538463,16.592307692307692,17.933076923076925,19.273846153846154,20.614615384615384,21.955384615384617,23.296153846153846,24.636923076923075,25.97769230769231,27.318461538461538,28.659230769230767,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.237692307692308,13.905384615384616,14.573076923076924,15.240769230769232,15.90846153846154,16.576153846153847,17.243846153846153,17.911538461538463,18.57923076923077,19.24692307692308,19.914615384615384,20.582307692307694,{"y":21.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,12.603076923076923,12.636153846153846,12.669230769230769,12.702307692307693,12.735384615384616,12.768461538461539,12.801538461538462,12.834615384615384,12.867692307692307,12.900769230769232,12.933846153846154,12.966923076923077,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >